Can the pharmaceutical industry reduce attrition rates?
The DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Part of the attrition may be due to low animal-to-human translational success rates; the so-called “translational failure” [3].”
From Animal to human translation: a systematic scoping review of reported concordance rates (2019) · cites this paper as [3]
In the citing paper
“Even so, late-stage attritions are still frequent [11].”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [11]
In the citing paper
“Inhibition of the hERG channel can be an indicator of the APD prolongation and cardiotoxicity in early stages of drug development [11].”
From Cardiovascular disease models: A game changing paradigm in drug discovery and screening (2019) · cites this paper as [11]
In the citing paper
“Less than 20 years ago, developing a drug took ~12 years, cost under a billion dollars, and the biggest challenges were failures due to efficacy or toxicity-induced attrition2.”
From Exploiting machine learning for end-to-end drug discovery and development (2019) · cites this paper as [2]
Citations
Cites
The price of innovation: new estimates of drug development costs
DiMasi, J. A., Hansen, R. W., & Grabowski, H. G. (2003) · Journal of Health Economics · doi:10.1016/s0167-6296(02)00126-1 · Cited by 4,265 · cited 1×
“In 2001, the costs of discovering and developing a drug were of the order of US d804 millio”
BackgroundRoberds, S. L. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.12.1317 · Cited by 705 · cited 1×
“We have, in a similar manner, provided very strong evidence that inhibition of β-secretase inhibits the production of amyloid-β in knockout mic”
ResultGowen, M., Lazner, F., Dodds, R., Kapadia, R., Feild, J., Tavaria, M., Bertoncello, I., Drake, F., Zavarselk, S., Tellis, I., et al. (1999) · Journal of Bone and Mineral Research · doi:10.1359/jbmr.1999.14.10.1654 · Cited by 490
Self-citationMa, P., & Zemmel, R. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd884 · Cited by 174
Booth, B. L., Glassman, R. H., & Ma, P. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1158 · Cited by 84
An animal model for pycnodysostosis: the role of cathepsin K in bone remodelling
Lazner, F., Gowen, M., & Kola, I. (1999) · Molecular Medicine Today · doi:10.1016/s1357-4310(99)01563-4 · Cited by 18 · cited 1×
“and that cathepsin K is involved in bone resorption (further compelling proof of mechanism is provided by humans with pycnodysostosi”
BackgroundSelf-citation2003 approvals: a year of innovation and upward trends
Frantz, S. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1327 · Cited by 15
Research works printed but not linked: 4
- Kola, I. & Rafferty, M. New technologies that may impact drug discovery in the 5–10 year timeframe workshop. 2002 Biomed. Expo Ann Arbor Michigan (data derived from Prous Science, Drugs News Prospect (2002).
- Fearn, C. J. IMS Health. The World Pharmaceutical Market Presented at the Strategic Management Review, Australia, 19–20 June (2002).
- Benjamin, G. A. & Lumley, C. E. Industry Success Rates 2003 Including Trends in Success Rates CMR Report Number 03–202 R (CMR International Surrey, UK, 2003).
- Van den Haak, M. A., Palachandran, J. & Benjamin, G. A. Performance Metrics in Global Pharmaceutical R&D, Company specific review 2002 for Merck & Co. (CMR International, Surrey, UK, 2003).
Cited by
Items 1,001–1,025 of 1,025
Artificial Intelligence Effecting a Paradigm Shift in Drug Development
Rashid, M. B. M. A. (2020) · SLAS TECHNOLOGY · doi:10.1177/2472630320956931 · Cited by 65
Park, S., Gianotti-Sommer, A., Molina-Estevez, F. J., Vanuytsel, K., Skvir, N., Leung, A., Rozelle, S. S., Shaikho, E. M., Weir, I., Jiang, Z., et al. (2017) · Stem Cell Reports · doi:10.1016/j.stemcr.2016.12.017 · Cited by 50
“All lines demonstrate robust coexpression of CD71 (transferrin receptor) and CD235 (glycophorin A), two markers of the erythroid lineage. attrition rates for drug development, as what works in vitro and subsequently in animal models may not always translate to the clinic (Kola and Landis, 2004).”
BackgroundEssential Medicinal Chemistry of Essential Medicines
Serafini, M., Cargnin, S., Massarotti, A., Pirali, T., & Genazzani, A. A. (2020) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.0c00415 · Cited by 46
Jacobi, N., Seeboeck, R., Hofmann, E., Schweiger, H., Smolinska, V., Mohr, T., Boyer, A., Sommergruber, W., Lechner, P., Pichler-Huebschmann, C., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.22475 · Cited by 43
“Lack of clinical efficacy and unacceptable toxicity are two main reasons for drug failure [14].”
BackgroundAligning physiology with psychology: Translational neuroscience in neuropsychiatric drug discovery
McArthur, R. A. (2017) · Neuroscience & Biobehavioral Reviews · doi:10.1016/j.neubiorev.2017.02.004 · Cited by 42
Qu, Y., Li, T., Liu, Z., Li, D., & Tong, W. (2023) · Drug Discovery Today · doi:10.1016/j.drudis.2023.103770 · Cited by 41
Gaskill, B. N., & Garner, J. P. (2017) · Lab Animal · doi:10.1038/laban.1218 · Cited by 41
Evolving toward a human-cell based and multiscale approach to drug discovery for CNS disorders
Schadt, E. E., Buchanan, S., Brennand, K. J., & Merchant, K. M. (2014) · Frontiers in Pharmacology · doi:10.3389/fphar.2014.00252 · Cited by 39
“Though many factors may contribute to the high rate of attrition, the major drivers for CNS disorders, are inadequate efficacy or margins of safety (Kola and Landis, 2004).”
BackgroundDaga, P. R., Bolger, M. B., Haworth, I. S., Clark, R. D., & Martin, E. J. (2018) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.7b00972 · Cited by 33
Naïve Bayesian Models for Vero Cell Cytotoxicity
Perryman, A. L., Patel, J. S., Russo, R., Singleton, E., Connell, N., Ekins, S., & Freundlich, J. S. (2018) · Pharmaceutical Research · doi:10.1007/s11095-018-2439-9 · Cited by 33
Genomics and Cardiovascular Drug Development
Plump, A. S., & Lum, P. Y. (2009) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2008.11.050 · Cited by 31
Hoogstraten, C. A., Smeitink, J. A. M., Russel, F. G. M., & Schirris, T. J. J. (2022) · Frontiers in Toxicology · doi:10.3389/ftox.2022.842396 · Cited by 30
Recommendations toward a human pathway-based approach to disease research
Marshall, L. J., Austin, C. P., Casey, W., Fitzpatrick, S. C., & Willett, C. (2018) · Drug Discovery Today · doi:10.1016/j.drudis.2018.05.038 · Cited by 28
Sieow, J. L., Penny, H. L., Gun, S. Y., Tan, L. Q., Duan, K., Yeong, J. P. S., Pang, A., Lim, D., Toh, H. C., Lim, T. K. H., et al. (2023) · International Journal of Molecular Sciences · doi:10.3390/ijms24010753 · Cited by 27
“However, therapeutic drugs that target cancer metabolism are complicated, as illustrated by the unexpected adverse effects that contribute to the failures of multiple Phase II and Phase III clinical trials, which may or may not be due to the highly hypoxic tumor environment and/or drug toxicity [65].”
Backgroundvan der Naald, M., Chamuleau, S. A. J., Menon, J. M. L., de Leeuw, W., de Haan, J., Duncker, D. J., & Wever, K. E. (2022) · BMJ Open Science · doi:10.1136/bmjos-2021-100259 · Cited by 26
Animal Paradigms to Assess Cognition with Translation to Humans
Wallace, T. L., Ballard, T. M., & Glavis-Bloom, C. (2015) · Handbook of Experimental Pharmacology · doi:10.1007/978-3-319-16522-6_2 · Cited by 26
Lekkala, V. K. R., Kang, S.-Y., Liu, J., Shrestha, S., Acharya, P., Joshi, P., Zolfaghar, M., Lee, M., Vanga, M. G., Jamdagneya, P., et al. (2024) · ACS Biomaterials Science & Engineering · doi:10.1021/acsbiomaterials.4c00179 · Cited by 25
Drug-mediated toxicity: illuminating the ‘bad’ in the test tube by means of cellular assays?
Tralau, T., & Luch, A. (2012) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2012.03.015 · Cited by 24
Benson, N., Matsuura, T., Smirnov, S., Demin, O., Jones, H. M., Dua, P., & van der Graaf, P. H. (2013) · Interface Focus · doi:10.1098/rsfs.2012.0071 · Cited by 20
“org Inrface Fcus 3:(20)120071 2 in an evaluation of pharmaceutical company productivity, which concluded that only a small proportion of the targets investigated lead to a marketed drug, with the percentage of first in human trial registered drugs that are subsequently approved currently being about 10 per cent [2].”
BackgroundData mining for potential adverse drug–drug interactions
Hammann, F., & Drewe, J. (2014) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2014.894507 · Cited by 19
“While in the 1990s, the predominant reasons for attrition were unsatisfactory bioavailability and pharmacokinetics, attritions currently tend to be caused by lack of efficacy and toxicology [1].”
BackgroundUdawatte, N. S., Kang, S. W., Wang, Y., Arumugam, T. V., & Seneviratne, C. J. (2020) · Frontiers in Pharmacology · doi:10.3389/fphar.2020.00511 · Cited by 17
Alcohol-abuse drug disulfiram targets pediatric glioma via MLL degradation
Meier, S., Cantilena, S., Niklison Chirou, M. V., Anderson, J., Hargrave, D., Salomoni, P., de Boer, J., & Michod, D. (2021) · Cell Death & Disease · doi:10.1038/s41419-021-04078-9 · Cited by 15
“Only around 5% of cancer drugs that enter clinical trials end up being successful [10].”
BackgroundDrug Development in Endometriosis and Adenomyosis: It Takes More Than Just Good Science
Groothuis, P. G., & Guo, S.-W. (2018) · Reproductive Sciences · doi:10.1177/1933719118785767 · Cited by 13
Kenna, J. G. (2017) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1080/17425255.2017.1290082 · Cited by 7
“ADRs that occur during human clinical trials are an important cause of terminated development of new candidate drugs [10,11].”
BackgroundTutorial on Drug Development for Central Nervous System
Yoon, H.-J., & Kim, J.-S. (2010) · Interdisciplinary Bio Central · doi:10.4051/ibc.2010.2.4.0009 · Cited by 1
Metadata
- Authors
- Kola, I., & Landis, J.
- Affiliations
- Merck & Co., Inc., Rahway, NJ, USA (United States) (US)
- Corresponding author
- Kola, Ismail
- ORCID
- Landis, John
- Venue
- Nature Reviews Drug Discovery
- Published
- 2004-08
- Volume
- 3
- Issue
- 8
- Pages
- 711-716
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1895993106
- Cited by
- 4,167
- References
- 7
- Citations by year
- 2026: 121 · 2025: 129 · 2024: 126 · 2023: 159 · 2022: 165 · 2021: 188 · 2020: 179 · 2019: 203 · 2018: 183 · 2017: 194 · 2016: 256 · 2015: 294 · 2014: 279 · 2013: 307 · 2012: 300
- FWCI
- 199.36
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Social Sciences › Economics, Econometrics and Finance › Economics and Econometrics › Pharmaceutical Economics and Policy
- Health Sciences › Nursing › Issues, ethics and legal aspects › Pharmaceutical industry and healthcare
- Health Sciences › Medicine › Public Health, Environmental and Occupational Health › Health and Medical Research Impacts
- Keywords
- pharmaceutical industry, attrition rates, R&D productivity, drug development costs, health care cost containment, drug costs, R&D investment
- MeSH terms
- Clinical Trials as Topic, Drug Industry, Humans, Pharmacokinetics, Drug Design, Drug Approval
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.